The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform

Jeanny B Aragonching - One of the best experts on this subject based on the ideXlab platform.

  • ipilimumab a potential Immunologic Agent in the treatment of metastatic castration resistant prostate cancer
    Cancer Biology & Therapy, 2014
    Co-Authors: Adam Kittai, Mariam Meshikhes, Jeanny B Aragonching
    Abstract:

    Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an Immunologic treatment should be advocated.

Adam Kittai - One of the best experts on this subject based on the ideXlab platform.

  • ipilimumab a potential Immunologic Agent in the treatment of metastatic castration resistant prostate cancer
    Cancer Biology & Therapy, 2014
    Co-Authors: Adam Kittai, Mariam Meshikhes, Jeanny B Aragonching
    Abstract:

    Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an Immunologic treatment should be advocated.

Mariam Meshikhes - One of the best experts on this subject based on the ideXlab platform.

  • ipilimumab a potential Immunologic Agent in the treatment of metastatic castration resistant prostate cancer
    Cancer Biology & Therapy, 2014
    Co-Authors: Adam Kittai, Mariam Meshikhes, Jeanny B Aragonching
    Abstract:

    Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an Immunologic treatment should be advocated.